Document Top

  • Evidence of VEGF expression in RCC

    ESMO guidelines 2009: treatment algorithm for RCC



     More

  • Prognostic implications of VEGF in RCC

    AVOREN: first‐line Avastin plus IFN



     More

  • Current treatment landscape

    AVOREN: safety of Avastin plus IFN



     More

  • AVOREN: tolerability following IFN dose reduction

    PFS as a clinical endpoint in RCC



     More

 
Educational webcasts

Educational webcasts

A series of webcasts highlighting some of the key learning points from scientific and clinical data.
Experienced physicians and scientists share their thoughts on the development of anticancer agents and discuss the options available for the treatment of cancer.

More

  • Expert perspective

    Expert perspective

    Targeting angiogenesis (Prof Joaquin Bellmunt)

    View

  • Controlling angiogenesis to control tumour growth

    Controlling angiogenesis to control tumour growth

    Avastin precisely targets VEGF to inhibit angiogenesis for continuous tumour control

    View

  • Effects of anti-VEGF treatment duration on treatment efficacy

    Effects of anti-VEGF treatment duration on treatment efficacy

    Preclinical models showing continuous VEGF suppression with anti-VEGF.

    View

Watch more

  • Bevacizumab plus IFN in mRCC

    Bevacizumab plus IFN in mRCC

    Latest clinical trial data on the efficacy of first-line Avastin plus IFN in mRCC (Dr Camillo Porta)

    View

  • Inhibiting angiogenesis

    Inhibiting angiogenesis

    Inhibiting angiogenesis: a mechanistic evaluation (Prof Román Pérez‐Soler)

    View

  • Clinical endpoints in oncology

    Clinical endpoints in oncology

    A discussion of clinical trial endpoints used in oncology trials and how these translate into patient benefit (Dr Artur Katz)

    View

Watch more

Upcoming Conferences

  • France
    EAU
    ,
    Paris, France
    24-28 February 2012
  • USA
    AACR
    ,
    Chicago, IL, USA
    31 March 2012 - 04 April 2012
  • Spain
    EONS
    ,
    Valencia, Spain
    26-27 April 2012

More upcoming conferences

x

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.

OK Cancel